Tenon Medical Reports Eight New USPTO Patents Issued in 2026 Fiscal Year
Tenon Medical announced 8 new patents issued by the USPTO so far in its 2026 fiscal year, covering systems and methods related to its Catamaran SI Joint Fusion System.
Tenon Medical, Inc. (NASDAQ:TNON) said the United States Patent and Trademark Office has issued 8 new patents to the company so far in its 2026 fiscal year. The company said the additions relate to systems and methods connected with its Catamaran SI Joint Fusion System.
Following the latest issuances, Tenon said it has 38 issued U.S. patents and 9 international patents. It also has 31 U.S. and foreign patent applications pending.
The new patents cover strategic system and method claims. Tenon said they provide underlying protection for Catamaran, which is designed for use in sacroiliac joint treatment. The company is also seeking further patent protection for both Catamaran and its SImmetry + SI Joint Fusion System.
Tenon said protection for both the implant and the method used to deliver it may create barriers for competitors seeking to replicate the Catamaran procedure. The company also described its intellectual property position as relevant to physician adoption and its long-term commercial strategy.
Richard Ginn, Tenon’s Chief Technology Officer, Chief Operations Officer and Director, said the company develops its systems with input from physicians who use them and from physician advisers. He attributed the 8 new patents to that feedback.
Tenon currently offers two systems for treating a diseased sacroiliac joint. Catamaran uses a single titanium implant in a less invasive approach. SImmetry + provides a minimally invasive lateral-access solution based on established orthopaedic fusion principles.
Tenon acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry + system, in August 2025. The company said its systems have applications in SI joint fusion, spinal fusion and deformity adjuncts.
Since the national launch of Catamaran in October 2022, Tenon has identified three commercial opportunities: primary SI Joint procedures, revision procedures involving failed SI Joint implants and SI-Joint fusion used as an adjunct to a spine fusion construct.
Based on market research and internal estimates, Tenon believes the potential U.S. market for surgical treatment of SI joint dysfunction represents approximately 270,000 procedures and approximately $2.1 billion annually. The company cites its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 27, 2026, for these figures.
Tenon said it anticipates further additions to its intellectual property portfolio and several product launches in the coming quarters. The company cautioned that pending patent applications may not result in issued patents, while issued patents may be challenged, invalidated, circumvented or found unenforceable, or may not provide meaningful protection.
The company also stated that its issued patents are expected to expire beginning around 2031. It warned that product launches may be delayed or may not receive required regulatory clearance, and that the market for its products may be smaller than estimated.
Tenon said its statements about future patent issuances, product launches, regulatory clearances, procedure adoption, revenue growth and commercial performance are forward-looking. It cautioned that actual results may differ materially from its expectations.
Tenon Medical said the USPTO has issued 8 new patents to the company so far in its 2026 fiscal year.
The portfolio now includes 38 issued U.S. patents, 9 international patents and 31 U.S. and foreign patent applications pending.
The latest patents cover systems and methods associated with the Catamaran SI Joint Fusion System.
Tenon is pursuing additional protection for Catamaran and SImmetry + and anticipates further intellectual property additions and several product launches in the coming quarters.
The company identified risks including patent challenges, possible non-issuance of pending applications, regulatory delays and an estimated patent-expiration beginning around 2031.
Tenon Medical announced that the United States Patent and Trademark Office had issued 8 new patents to the company so far in its 2026 fiscal year. The patents cover strategic systems and method claims relating to the company’s Catamaran SI Joint Fusion System.
Tenon Medical said its portfolio includes 38 issued U.S. patents, 9 international patents and 31 U.S. and foreign patent applications pending. The company is pursuing additional patent protection across its Catamaran and SImmetry + SI Joint Fusion System platforms.
Tenon Medical said the newly issued patents provide underlying protection for its Catamaran SI Joint Fusion System through strategic systems and method claims. The company said the portfolio is intended to protect both the implant and the method of delivering it.
Richard Ginn, Tenon Medical’s Chief Technology Officer, Chief Operations Officer and Director, said the company listens to physicians using its systems and to its physician advisers. He said the 8 new patents resulted directly from that feedback.
Tenon Medical said protecting both the implant and the method of delivering it may create barriers for competitors seeking to replicate the Catamaran procedure. The company also said it views a defensible intellectual property position as important to physician adoption and its long-term commercial strategy.
Tenon Medical offers the Catamaran SI Joint Fusion System and the SImmetry + SI Joint Fusion System to treat a diseased sacroiliac joint. Catamaran uses a single, robust titanium implant in a less invasive approach, while SImmetry + provides a minimally invasive SI Joint lateral access solution incorporating well-established orthopaedic fusion principles.
Tenon Medical said its commercial opportunities include primary SI Joint procedures, revision procedures for failed SI Joint implants and SI-Joint fusion adjuncts to a spine fusion construct. The company’s portfolio also has applications in SI joint fusion, spinal fusion and deformity adjuncts.
Tenon Medical acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry + SI Joint Fusion System, in August 2025. The company said the system was acquired as part of that transaction.
Based on market research and internal estimates, Tenon Medical believes the potential U.S. market for surgical treatment of SI joint dysfunction represents approximately 270,000 procedures and approximately $2.1 billion annually. The figures are referenced to Tenon Medical’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Tenon Medical said it anticipates continued additions to its intellectual property portfolio along with several product launches in the coming quarters. The company’s forward-looking statements note that product launches may be delayed or may not receive required regulatory clearance, and that pending patent applications may not issue.
Richard Ginn said Tenon Medical believes the new patents, together with the rest of its portfolio, give it a foundation to drive procedure adoption and revenue growth as it expands care for patients with sacro-pelvic disorders. This is a company statement about anticipated future performance, and the release cautions that actual results may differ materially from its expectations.
Tenon Medical said pending patent applications may not issue and that issued patents may be challenged, invalidated, circumvented or found unenforceable, or may not provide meaningful protection. The company also said its issued patents are expected to expire beginning around 2031 and that the market for its products may be smaller than estimated.
Tenon Medical identifies itself as listed on NASDAQ under the ticker symbol TNON.